Predictors of COVID-19 severity and outcomes in Indian patients with rheumatic diseases: a prospective cohort study
et al., Rheumatology Advances in Practice, doi:10.1093/rap/rkad025
, Predictors of COVID-19 severity and outcomes in Indian patients with rheumatic diseases: a prospective cohort.., Rheumatology Advances in Practice, doi:10.1093/rap/rkad025
Prospective study of 64 rheumatic disease patients with COVID-19, showing no significant difference in outcomes with HCQ use.Although the 20% lower mortality is not statistically significant, it is consistent with the significant 22% lower mortality [18‑27%] from meta analysis of the 232 mortality results to date.
|
risk of death, 20.0% lower, OR 0.80, p = 0.80, treatment 23, control 41, RR approximated with OR.
|
|
risk of hospitalization, no change, OR 1.00, p = 0.94, treatment 23, control 41, RR approximated with OR.
|
|
risk of severe case, 40.0% lower, OR 0.60, p = 0.37, treatment 23, control 41, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Mathew et al., 28 Feb 2023, prospective, India, peer-reviewed, 8 authors, study period April 2020 - October 2021.
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.